NasdaqGM - Delayed Quote • USD
Invivyd, Inc. (IVVD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:25 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.47 | -0.4 | -0.99 | -0.52 |
| Low Estimate | -0.57 | -0.46 | -1.16 | -0.93 |
| High Estimate | -0.39 | -0.33 | -0.84 | -0.03 |
| Year Ago EPS | -0.32 | -0.46 | -1.81 | -0.99 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -- | 6M | 176.45M | 325.56M |
| Low Estimate | -- | 5M | 152M | 257.1M |
| High Estimate | -- | 6.9M | 212.11M | 402.1M |
| Year Ago Sales | -- | -- | -- | 176.45M |
| Sales Growth (year/est) | -- | -- | -- | 84.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.34 | -0.5 | -0.42 |
| EPS Actual | -0.32 | -0.46 | -0.36 | -0.67 |
| Difference | -0.02 | -0.12 | 0.14 | -0.25 |
| Surprise % | -6.70% | -35.30% | 28.00% | -59.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.47 | -0.4 | -0.99 | -0.52 |
| 7 Days Ago | -0.47 | -0.4 | -0.99 | -0.52 |
| 30 Days Ago | -0.4 | -0.43 | -1.23 | -0.04 |
| 60 Days Ago | -0.38 | -0.39 | -1.41 | -0.32 |
| 90 Days Ago | -0.38 | -0.39 | -1.41 | -0.32 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 3 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | IVVD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -46.90% | -- | -- | 5.40% |
| Next Qtr. | 13.00% | -- | -- | 10.90% |
| Current Year | 45.30% | -- | -- | 4.50% |
| Next Year | 47.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Guggenheim: Neutral to Buy | 4/5/2024 |
| Upgrade | Morgan Stanley: Equal-Weight to Overweight | 3/26/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/25/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/18/2024 |
| Upgrade | Morgan Stanley: Underweight to Equal-Weight | 12/19/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
Related Tickers
RLYB Rallybio Corporation
1.7000
+3.03%
BTAI BioXcel Therapeutics, Inc.
2.6300
+0.77%
LCTX Lineage Cell Therapeutics, Inc.
1.1400
+2.70%
TRML Tourmaline Bio, Inc.
15.68
-2.00%
HOTH Hoth Therapeutics, Inc.
1.1600
0.00%
ETNB 89bio, Inc.
8.26
+0.12%
IMNN Imunon, Inc.
1.4400
0.00%
BYSI BeyondSpring Inc.
2.1300
-6.17%
GTHX G1 Therapeutics, Inc.
3.9900
+3.37%
ANTX AN2 Therapeutics, Inc.
2.3200
+1.75%